• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Cassava Sciences Inc.

    7/29/25 11:22:13 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAVA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Cassava Sciences Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    14817C107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14817C107


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,154,175.00
    8Shared Dispositive Power

    15,897.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,170,072.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.49 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cassava Sciences Inc
    (b)Address of issuer's principal executive offices:

    7801 North Capital of Texas Hi, Suite 260, Austin, TX, 78731
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    14817C107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2170072
    (b)Percent of class:

    4.49  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2154175

     (iv) Shared power to dispose or to direct the disposition of:

    15897

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $SAVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAVA

    DatePrice TargetRatingAnalyst
    11/26/2024Buy → Neutral
    H.C. Wainwright
    10/8/2024$116.00Neutral → Buy
    H.C. Wainwright
    7/1/2024Buy → Neutral
    H.C. Wainwright
    11/16/2022$44.00Buy → Neutral
    B. Riley Securities
    1/24/2022$108.00 → $72.00Buy
    B. Riley Securities
    7/20/2021$97.00 → $124.00Buy
    HC Wainwright & Co.
    7/15/2021$100.00Overweight → Neutral
    Cantor Fitzgerald
    7/7/2021$80.00 → $190.00Buy
    Maxim Group
    More analyst ratings

    $SAVA
    SEC Filings

    View All

    SEC Form 10-Q filed by Cassava Sciences Inc.

    10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/14/25 8:15:27 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/14/25 7:45:28 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CASSAVA SCIENCES INC (0001069530) (Filer)

    8/4/25 7:45:28 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    11/26/24 7:44:43 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Cassava Sciences from Neutral to Buy and set a new price target of $116.00

    10/8/24 8:06:57 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral

    7/1/24 7:48:24 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

    Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development

    8/7/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

    Study in a TSC mouse model further demonstrates simufilam's anti-seizure activityStudy conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout modelFirst clinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) --  Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy. Most individuals with TSC experience

    8/4/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Scannon Patrick J Md Phd

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    7/16/25 4:04:20 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Anderson Robert Eugene Jr

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    5/27/25 4:26:31 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gravier Pierre

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    5/27/25 4:23:30 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Financials

    Live finance-specific insights

    View All

    Cassava Sciences to Hold Corporate Update on November 25th

    AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.    Event Details:    Date: Monday, November 25th Time: 8:00 a.m. Eastern Time Webcast: https://lifescievents.com/event/cassava/    A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnolog

    11/24/24 8:01:09 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

    AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.   Event details:  Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy   A replay of the audio webcast will also be available on the "Company Presentations" page of the Cassava Sciences website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    10/31/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

    AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr   A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo

    8/1/24 8:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/13/24 5:01:04 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cassava Sciences Inc. (Amendment)

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    2/1/24 4:00:47 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAVA
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Reports Q2 2025 Financials Results and Provides Business Update

    Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilamAdvanced settlement negotiations ongoing to resolve certain securities litigation; $31.25 million estimated loss contingency recorded in Q2 for resolution$112.4 million in cash and cash equivalents at June 30, 2025 AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for c

    8/14/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

    Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy and other neurological disordersClinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development

    8/7/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

    As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bor

    5/1/25 7:30:00 AM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care